Venture Partner, The Column Group
Jeff Goater was appointed Interim Chief Executive Officer in January 2022, coincident with the transition of John Josey to Chairman of the Board. Jeff is also a member of the Board of Directors of Atavistik Bio and a Venture Partner at The Column Group. Previously, he served as Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously, Jeff spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy and holds master’s degrees in microbiology/immunology (MS), pathology (MS) and business administration (MBA) from the University of Rochester. Jeff also currently serves on the boards of Ribon Therapeutics, Surface Oncology, Vaccinex and LogicBio Therapeutics.